In the subgroup analysis, there was a significant interaction indicating a consistent AF-preventing capacity of SGLT2 inhibitors in the population of patients with HFrEF or in patients enrolled in RCTs not focused on HF, as opposed to RCTs including patients with HFmrEF/HFpEF or HF regardless of LVEF class (P for subgroup differences < 0.01). This evidence concerns the gene SLC5A2 and hydrops fetalis.